Novartis has relied on acquisitions to sharpen the pharma giant’s focus on cutting-edge drugs. Reuters
Novartis has relied on acquisitions to sharpen the pharma giant’s focus on cutting-edge drugs. Reuters

Economy

Swiss drugmaker Novartis buys Medicines Company in $6.8bn deal

Shareholders of New Jersey-based Medicines Company will receive $85 a share

Bloomberg

November 25, 2019